Origin of residual tumor masses in {BRCA}1/2-driven ovarian carcinomas treated by neoadjuvant chemotherapy: selection of preexisting {BRCA}1/2-proficient tumor cells but not the gain of second {ORF}-restoring mutation

Anna Sokolenko; Elena Preobrazhenskaya; Claudia Marchetti; Angelo Piermattei; Fedor Zagrebin; Ekatherina Kuligina; Tatiana Gorodnova; Matteo Pavone; Alexandr Ivantsov; Ilya Bizin; Giovanni Scambia; Igor Berlev; Anna Fagotti; Evgeny Imyanitov

doi:10.1159/000533591

Origin of residual tumor masses in {BRCA}1/2-driven ovarian carcinomas treated by neoadjuvant chemotherapy: selection of preexisting {BRCA}1/2-proficient tumor cells but not the gain of second {ORF}-restoring mutation

Anna Sokolenko
, Elena Preobrazhenskaya
, Claudia Marchetti
, Angelo Piermattei
, Fedor Zagrebin
, Ekatherina Kuligina
, Tatiana Gorodnova
, Matteo Pavone
, Alexandr Ivantsov
, Ilya Bizin
, Giovanni Scambia
, Igor Berlev
, Anna Fagotti
, Evgeny Imyanitov

Russian Ministry of Health

Research output: Contribution to journal › Article

Original language	English
Pages (from-to)	1-5
Number of pages	5
Journal	Pathobiology
Volume	2023
DOIs	https://doi.org/10.1159/000533591
Publication status	Published - 2023

Keywords

BRCA1/2

Access to Document

10.1159/000533591

Cite this

Sokolenko, A., Preobrazhenskaya, E., Marchetti, C., Piermattei, A., Zagrebin, F., Kuligina, E., Gorodnova, T., Pavone, M., Ivantsov, A., Bizin, I., Scambia, G., Berlev, I., Fagotti, A., & Imyanitov, E. (2023). Origin of residual tumor masses in {BRCA}1/2-driven ovarian carcinomas treated by neoadjuvant chemotherapy: selection of preexisting {BRCA}1/2-proficient tumor cells but not the gain of second {ORF}-restoring mutation. Pathobiology, 2023, 1-5. https://doi.org/10.1159/000533591

@article{f30b0fbfef1d411a9f68b69a3b750f48,

title = "Origin of residual tumor masses in \{BRCA\}1/2-driven ovarian carcinomas treated by neoadjuvant chemotherapy: selection of preexisting \{BRCA\}1/2-proficient tumor cells but not the gain of second \{ORF\}-restoring mutation",

keywords = "BRCA1/2, BRCA1/2",

author = "Anna Sokolenko and Elena Preobrazhenskaya and Claudia Marchetti and Angelo Piermattei and Fedor Zagrebin and Ekatherina Kuligina and Tatiana Gorodnova and Matteo Pavone and Alexandr Ivantsov and Ilya Bizin and Giovanni Scambia and Igor Berlev and Anna Fagotti and Evgeny Imyanitov",

year = "2023",

doi = "10.1159/000533591",

language = "English",

volume = "2023",

pages = "1--5",

journal = "Pathobiology",

issn = "1015-2008",

publisher = "S. Karger AG",

}

Sokolenko, A, Preobrazhenskaya, E, Marchetti, C, Piermattei, A, Zagrebin, F, Kuligina, E, Gorodnova, T, Pavone, M, Ivantsov, A, Bizin, I, Scambia, G, Berlev, I, Fagotti, A & Imyanitov, E 2023, 'Origin of residual tumor masses in {BRCA}1/2-driven ovarian carcinomas treated by neoadjuvant chemotherapy: selection of preexisting {BRCA}1/2-proficient tumor cells but not the gain of second {ORF}-restoring mutation', Pathobiology, vol. 2023, pp. 1-5. https://doi.org/10.1159/000533591

Origin of residual tumor masses in {BRCA}1/2-driven ovarian carcinomas treated by neoadjuvant chemotherapy: selection of preexisting {BRCA}1/2-proficient tumor cells but not the gain of second {ORF}-restoring mutation. / Sokolenko, Anna; Preobrazhenskaya, Elena; Marchetti, Claudia et al.
In: Pathobiology, Vol. 2023, 2023, p. 1-5.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Origin of residual tumor masses in {BRCA}1/2-driven ovarian carcinomas treated by neoadjuvant chemotherapy: selection of preexisting {BRCA}1/2-proficient tumor cells but not the gain of second {ORF}-restoring mutation

AU - Sokolenko, Anna

AU - Preobrazhenskaya, Elena

AU - Marchetti, Claudia

AU - Piermattei, Angelo

AU - Zagrebin, Fedor

AU - Kuligina, Ekatherina

AU - Gorodnova, Tatiana

AU - Pavone, Matteo

AU - Ivantsov, Alexandr

AU - Bizin, Ilya

AU - Scambia, Giovanni

AU - Berlev, Igor

AU - Fagotti, Anna

AU - Imyanitov, Evgeny

PY - 2023

Y1 - 2023

KW - BRCA1/2

UR - http://hdl.handle.net/10807/302144

U2 - 10.1159/000533591

DO - 10.1159/000533591

M3 - Article

SN - 1015-2008

VL - 2023

SP - 1

EP - 5

JO - Pathobiology

JF - Pathobiology

ER -

Origin of residual tumor masses in {BRCA}1/2-driven ovarian carcinomas treated by neoadjuvant chemotherapy: selection of preexisting {BRCA}1/2-proficient tumor cells but not the gain of second {ORF}-restoring mutation

Keywords

Access to Document

Other files and links

Cite this